

Program

[Interactive ProgramPROGRAM AT A GLANCE](#)

14:00 – 14:10

WELCOME ADDRESS

Plenary Hall (Ballsaal)

Dirk Busch, Technical University of Munich, Germany

Adi Barzel, Tel-Aviv University, Israel

14:10 – 14:45

KEYNOTE LECTURE: BALANCING PERSISTENCE AND EFFECTOR FUNCTIONS IN CAR T-CELLS

Plenary Hall (Ballsaal)

Chair: Adi Barzel, Tel-Aviv University, Israel

14:10 – 14:35 Presentation

Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA

14:35-14:45 – Q&A

14:10 – 15:45

SESSION 1: REAL-WORLD EXPERIENCE, NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES

Plenary Hall (Ballsaal)

Chairs: Chiara Bonini, Vita-Salute San Raffaele University, Italy

Michael Hudecek, LETSimmun Consortium, Germany

14:10 – 14:35

KEYNOTE LECTURE: CONQUERING RESISTANCE MECHANISMS IN ENGINEERED CELL THERAPIES

Stanley Riddell, Fred Hutchinson Cancer Research Center, USA

14:35 -14:50

RWE: BEYOND CRS AND ICANS: HEMATOTOXICITY AND INFECTIONS AS DRIVERS OF CAR-T NRM

Marion Subklewe, LETSimmun Consortium, Germany

14:50 – 15:05

CLINICAL LEARNINGS AND NEW FRONTIERS FOR B CELL-DRIVEN DISEASES

Jennifer Brogdon, Novartis, USA

15:05 – 15:45

Panel discussion

15:45 – 16:30

COFFEE BREAK, YOUNG SCIENTIST FORUM, EXHIBITION & POSTER VIEWING

Exhibition & Networking Area (Grosser Saal)

15:55 – 16:25

THE RESEARCHER'S JOURNEY: OVERCOMING EARLY CAREER CHALLENGES

Moderator: Stanley Riddell, Fred Hutchinson Cancer Research Center, USA

Young scientists:

Alon Richter, Tel Aviv University, Israel

Sophia Stock, Ludwig Maximilian University of Munich, Germany

Bettina Bernard, Technical University of Munich, Germany

Faculty members:

Marion Subklewe, LETSimmun Consortium, Germany

Hans Stauss, University College London, UK

Chiara Bonini, Vita-Salute San Raffaele University, Italy

16:30 – 18:15

SESSION 2: SUPERPOWERED LYMPHOCYTES

Plenary Hall (Ballsaal)

Chairs: **Mirjam Heemskerk**, Leiden University Medical Center, Netherlands

Wolfgang Kastenmüller, University of Wurzburg, Germany

16:30 – 16:45

A PRIVATE CROSSTALK ESTABLISHED BY TUMOR-TARGETED CYTOKINE RELEASE RESCUES CAR-T ACTIVITY AND ENGAGES HOST T-CELLS AGAINST GLIOBLASTOMA

Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy, Italy

16:45 – 17:00

ENGINEERING T-CELLS FOR SUPERIOR PERFORMANCE

George Coukos, Ludwig Cancer Research Lausanne Branch, Switzerland

17:00 – 17:15

OVERCOMING T-CELL SENESENCE BY GENOME EDITING

Chiara Bonini, Vita-Salute San Raffaele University, Italy

17:15 – 17:25

STAB-T-CELLS SECRETING ANTI-BCMA T-CELL ENGAGERS DEMONSTRATE SUPERIOR ANTITUMOR ACTIVITY COMPARED TO ANTI-BCMA CAR T-CELLS

Javier Arroyo-Rodenas, University Hospital October 12, Spain

17:25 – 17:35

T-CELL-MEDIATED ADCC AS A THERAPEUTIC STRATEGY FOR SOLID CANCERS

Yaron Carmi, Tel Aviv University, Israel

17:35 – 17:45

ADDRESSING TUMOUR MICROENVIRONMENT RESISTANCE MECHANISMS TO IMPROVE CAR T-CELL EFFICACY

Paul Neeson, Peter MacCallum Cancer Centre, Australia

17:45 – 18:15

Panel discussion

18:15 – 20:00

MEET THE POSTER PRESENTERS & WELCOME RECEPTION

Exhibition & Networking Area (Grosser Saal & Forums 4-7)

09:00 – 10:10

SESSION 3: NON-VIRAL CAR/TCR GENE TARGETING

Plenary Hall (Ballsaal)

Chairs: Antonio Bertoletti, A*STAR, Singapore

Elvira D'Ippolito, Technical University of Munich, Germany

09:00 – 09:15

COMBINING CRISPR AND TRANSPOSON-BASED TECHNOLOGIES FOR IMPROVED CAR-T THERAPIES

Juan Roberto Rodriguez-Madoz, Cima Universidad de Navarra, Spain

09:15 – 09:30

CAR-Ts GOING NON-VIRAL FROM BENCH TO BEDSIDE (AND BACK)

Michael Hudecek, LETSimmun Consortium, Germany

09:30 – 09:40

CELL AVIDITY NEXT GENERATION BINDING: UNDERSTAND THE MECHANISM OF ACTION THROUGH CELL-CELL BINDING

Andrea Candelli, Lumicks, Netherlands

09:40 – 10:10

Panel Discussion

10:10 – 10:50

COFFEE BREAK, EXHIBITION, INDUSTRY PRESENTATIONS &

POSTER VIEWING

Exhibition & Networking Area (Grosser Saal)

10:30 – 10:40

GENOME EDITING FOR THE TREATMENT OF HUMAN DISEASE NETWORK (GenE-HumDi). COST ACTION CA21113

Daniela Benati, University of Modena and Reggio Emilia, Italy

10:50 – 12:20

SESSION 4: CUTTING-EDGE INDUSTRY ADVANCEMENTS

Plenary Hall (Ballsaal)

Chairs: Johanna Olweus, Oslo University, Norway

Sebastian Kobold, LMU Hospital, Germany

10:50 – 11:20

ENHANCING CELL THERAPY MANUFACTURING: SCALABLE AND FLEXIBLE SOLUTIONS FOR T CELL ISOLATION

Hany Meås, Thermo Fisher Scientific, Norway

11:20 – 11:35

AUTOMATED, SCALABLE IMMUNE CELL CIRCULATION PLATFORM FOR CANCER MODELS

Mark Lyons, Hooke Bio, Ireland

11:35 – 11:50

MOLECULAR PIXELATION QUANTIFIES CAR T ACTIVITY AND REVEALS CANCER – SPECIFIC PROTEIN PATTERNS OF INDIVIDUAL CELLS

Hanna van Ooijen, Pixelgen Technologies, Sweden

11:50 – 12:20

Panel Discussion

12:20 – 13:50

LUNCH BREAK, TOP 10 POSTER PRESENTATIONS,

EXHIBITION & POSTER VIEWING

Exhibition & Networking Area (Grosser Saal)

12:40 – 13:30 TOP 10 POSTER PRESENTATIONS

Chair: Maayan Zaba, Tel Aviv University, Israel

12:40 – 12:45

T CELL ENGINEERING USING V(D)J RECOMBINATION ALLOWS TUMOR GROWTH INHIBITION IN MICE

Tal Veig, Tel Aviv University, Israel

12:45 – 12:50

FCγRI-DRIVEN T CELL-MEDIATED ADCC AS A STRATEGY FOR TREATING SOLID TUMORS

Alon Richter, Tel Aviv University, Israel

12:50 – 12:55

PROSTANOID-INSENSITIVE CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS MEDIATE THERAPEUTIC EFFICACY IN SOLID CANCER MODELS

Lisa Gregor, LMU Clinic, Germany

12:55 – 13:00

TUMOR-INFILTRATING LYMPHOCYTES SECRETING T CELL-ENGAGING ANTIBODIES INDUCE REGRESSION OF PATIENT-DERIVED LUNG CANCER XENOGRAFTS

Anaïs Jiménez-Reinoso, 12 de Octubre University Hospital, Spain

13:00 – 13:05

FINE-TUNING SIGNAL-STRENGTH IN T CELL-BASED ADOPTIVE CELLULAR ANTI-CANCER THERAPIES: TRANSIENT LOW-DOSE MEK-INHIBITION FOR POTENTIATING ENGINEERED T CELLS

Franziska Füchsl, Technical University Munich, Germany

13:05 – 13:10

OPTIMIZING ADOPTIVE IMMUNOTHERAPY OF LEUKEMIA WITH CD1C-REDIRECTED T AND INKT CELLS

Michela Consonni, IRCCS San Raffaele Scientific Institute,

Italy

13:10 – 13:15

POTENCY TUNED NOVEL CD70 CAR-T CELLS WITH A COMPUTATIONALLY DESIGNED CD27:CD70 BINDING INTERFACE FOR ACUTE MYELOID LEUKEMIA

Tiffany Que, UNIL-CHUV, Switzerland

13:15 – 13:20

T CELL STIMULATION AND PIFITHRIN-ALPHA CONTROL DNA DELETION SIZES AND ANEUPLOIDY IN CRISPR-EDITED HUMAN T CELLS

Jule Müschen, Technical University Munich, Germany

13:20 – 13:25

UNRAVELING T-CELL-RECEPTOR (TCR) SPECIFICITY: TCR LANGUAGE MODELS TO PREDICT AND DESIGN TCR:EPITOPE INTERACTIONS

Adrian Straub, Technical University Munich, Germany

13:25- 13:30

ENGINEERING B CELLS THROUGH THE INTEGRATION OF HIV-RECEPTOR EXONS

Ata Ul Wakeel Ahmad, MDC Berlin, Germany

13:50 – 15:15

SESSION 5: CAR/TCR MRNA THERAPIES

Plenary Hall (Ballsaal)

Chairs: Adi Barzel, Tel Aviv University, Israel

Jürgen Rüland, TUM University Hospital, Germany

13:50 – 14:15

KEYNOTE LECTURE: NUCLEOSIDE-MODIFIED mRNA-LNP THERAPEUTICS

Drew Weissman, University of Pennsylvania School of Medicine, USA

14:15 – 14:30

MRNA-BASED T-CELL ENGINEERING FOR VIRUS-RELATED CANCERS (HBV-HCC) AND VIRAL INFECTIONS

Antonio Bertoletti, A*STAR, Singapore

14:30 – 14:40

ANTIGEN-SPECIFIC AND BYSTANDER ANTITUMOR ACTIVITY OF RNA CAR T-CELLS AGAINST GBM-ASSOCIATED ANTIGEN PTPRZ1

Darel Martínez Bedoya, University of Geneva, Switzerland

14:40 – 15:15

Panel Discussion

15:15 – 15:25

SHORT BREAK

15:25 – 16:35

SESSION 6: UNIVERSAL DONOR CELLS & ADVANCED TCR ENGINEERING

Plenary Hall (Ballsaal)

Chairs: **Darel Martinez Bedoya**, University of Geneva, Switzerland

Eva Bräunlein, TUM University Hospital, Germany

15:25 – 15:40

TARGETING CANCER WITH T-CELL RECEPTOR-ENGINEERED T-CELLS

Johanna Olweus, Oslo University, Norway

15:40 – 15:55

TARGETED ENGINEERING OF RECOMBINANT TCR-T CELLS FOR THERAPY AND LIGAND PREDICTION

Dirk Busch, Technical University of Munich, Germany

15:55 – 16:05

DISRUPTED KINASE (DISK) CAR T-CELLS FOR ALLOGENEIC THERAPY

Previtha Dawn Sakthi Vale, National University of Singapore, Singapore

16:05 – 16:35

Panel Discussion

16:35 – 17:30

COFFEE BREAK, EXPERT-LED INSIGHTS, EXHIBITION & POSTER VIEWING

Exhibition & Networking Area (Grosser Saal)

16:50 – 17:20

EXPERT-LED INSPIRATION: YOUR QUESTIONS, OUR INSIGHTS

Moderator: **Stanley Riddell**, Fred Hutchinson Cancer Research Center, USA

Discussants:

Drew Weissman, University of Pennsylvania School of Medicine, USA

Carl June, University of Pennsylvania, USA

17:30 – 19:00

SESSION 7: UPDATED CLINICAL DATA & NOVEL DEVELOPMENTS

Plenary Hall (Ballsaal)

Chairs: **Yaron Carmi**, Tel Aviv University, Israel

Annette Künkele-Langer, Charite – Berlin University Medicine, Germany

17:30 – 17:55

KEYNOTE LECTURE: CAR T-CELLS – CURRENT STATUS AND OUTLOOK

Carl June, University of Pennsylvania, USA

17:55 – 18:10

ENGINEERING DE NOVO BINDER CAR-T CELL THERAPIES WITH GENERATIVE AI

Andrea Schmidts, Technical University of Munich, Germany

18:10 – 18:20

ALLOREACTIVE VERSUS IL-15 EX-VIVO-STIMULATED NK CELLS AS

ADOPTIVE CELL THERAPY IN HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC ACUTE LEUKEMIA: A PHASE I/II TRIAL (PHINK)

Carmen Mestre-Durán, Research Institute of the University Hospital La Paz (IdiPAZ), Spain

18:20 – 19:00

Panel discussion

08:30 – 09:30

SESSION 8: BEYOND ALPHA-BETA T-CELLS

Plenary Hall (Ballsaal)

Chairs: Hans Stauss, University College London, UK

Maik Luu, University Hospital of Wurzburg, Germany

08:30 – 08:45

FROM AUTOLOGOUS TO ALLOGENEIC CAR EFFECTOR CELLS: PUSHING THE BOUNDARIES FROM CANCER TO OTHER SEVERE DISEASES

Ulrike Koehl, Fraunhofer Institute for Cell Therapy and Immunology Leipzig, Germany

08:45 – 08:55

HSPC GENE EDITING FOR SPECIFIC ANTIBODY EXPRESSION THROUGH HUMORAL IMMUNE RESPONSES

Harald Hartweger, The Rockefeller University, United States

08:55 – 09:05

REPROGRAMING IMMUNOSUPPRESSIVE MICROENVIRONMENT IN THE SOLID TUMOR BY TARGETED DELIVERY OF TGF-B-BLOCKING SCFV FROM ANTIBODY-CAR-MACROPHAGES (AB-CAR-M)

Rio Sugimura, Hong Kong University, Hong Kong

09:05 – 09:30

Panel discussion

09:30 – 11:00

SESSION 9: TARGETING NON-MALIGNANT DISEASES

Plenary Hall (Ballsaal)

Chairs: Ulrike Koehl, Fraunhofer Institute for Cell Therapy and Immunology Leipzig, Germany

Ulrike Protzer, Technical University of Munich, Germany

09:30 – 09:45

CAR T-CELL TREATMENT IN AUTOIMMUNE DISEASE

Georg Schett, Friedrich-Alexander University of Erlangen-Nuremberg, Germany

09:45 – 10:00

CAR T-CELLS AGAINST IgE B CELLS

Adi Barzel, Tel Aviv University, Israel

10:00 – 10:15

MODIFICATION OF TCR/CD3 TO ENHANCE T-CELL FUNCTION

Hans Stauss, University College London, UK

10:15 – 10:30

CLINICAL AND TRANSLATIONAL STUDIES OF RESE-CEL (AN ANTI-CD19 CAR T THERAPY) IN MYOSITIS, SLE, AND SYSTEMIC SCLEROSIS: RESET PHASE I/II TRIALS

Samik Basu, Cabaletta, USA

10:30 – 10:40

BASE EDITING OF APDS1 AND APDS2 T-CELLS RESTORES PI3K DELTA SIGNALLING

Kate Orf, UCL, United Kingdom

10:40 – 11:00

Panel discussion

11:00 – 11:40

COFFEE BREAK, EXHIBITION & POSTER PRESENTATIONS

Exhibition & Networking Area (Grosser Saal)

11:40 – 12:40

SESSION 10: SELECTED ABSTRACTS FOR ORAL PRESENTATION

Plenary Hall (Ballsaal)

Chairs: Dirk Busch, Technical University of Munich, Germany
Adi Barzel, Tel-Aviv University, Israel

11:40 – 11:50

RAPID MACHINE LEARNING DRIVEN TARGET IDENTIFICATION IN TIL AND PERSONALISED TRANSGENIC TCR CELL THERAPIES

Edward Green, DKFZ, Germany

11:50 – 12:00

OVERCOMING BARRIERS FOR T-CELL THERAPY OF CHRONIC HEPATITIS B VIRUS INFECTION

Lisa Schiller, Technical University of Munich, Germany

12:00 – 12:10

SYSTEMIC DELIVERY OF CDH17 CAR T-CELLS ALLOWS EFFECTIVE AND SAFE TARGETING OF COLORECTAL CANCER LIVER METASTASES

Rita El Khoury, IRCCS San Raffaele Scientific Institute, Italy

12:10 – 12:20

DUAL TARGETING OF PD-L1 AND ERBB2 BY CAR-NK CELLS ENABLES SPECIFIC ELIMINATION OF SOLID TUMOR CELLS AND OVERCOMES IMMUNE ESCAPE VIA ANTIGEN LOSS

Jiri Eitler, Technical University of Dresden, Germany

12:20 – 12:40

Panel Discussion

12:40 – 13:45

SESSION 11: IN VIVO AND BEDSIDE T-CELL ENGINEERING

Plenary Hall (Ballsaal)

Chairs: Harald Hartweg, The Rockefeller University, United

States

Louisa v. Baumgarten, Ludwig Maximilian University of Munich, Germany

12:40 – 12:55

T-CELL TARGETED VECTORS FOR IN VIVO CAR DELIVERY

Christian Buchholz, PEI, Germany

12:55 – 13:10

EXTRACORPOREAL CAR GENE DELIVERY

David Peritt, Lupagen, USA

13:10 – 13:25

NOVEL NON-VIRAL DNA-BASED GENE THERAPY VECTOR FOR CAR T ENGINEERING IN VIVO

Jacek Lubelski, NanoCell, Netherlands

13:25 – 13:45

Panel Discussion

13:45 – 14:00

BEST POSTER ANNOUNCEMENT & CONFERENCE CLOSURE

Plenary Hall (Ballsaal)

Moderators: **Adi Barzel**, Tel-Aviv University, Israel

Dirk Busch, Technical University of Munich, Germany

13:45 – 13:50

ANNOUNCEMENT OF THE TOP 3 POSTERS

13:50 – 13:55

5 MIN PRESENTATION ON STAGE OF THE BEST POSTER RANKED 1st

13:55 – 14:00

CLOSING WORDS BY THE CONFERENCE CO-CHAIRS

***The program could be subject to changes.**